NCT04159987View on ClinicalTrials.gov

Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

July 19, 2024

Study Completion Date

July 19, 2024

Conditions
Spinal Muscular Atrophy
Interventions
OTHER

Spinraza intrathecal injection

The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).

Trial Locations (7)

13005

Hopital de la Timone - APHM, Marseille

31059

CHU de Toulouse, Toulouse

34090

CHU de Montpellier, Montpellier

59000

CHRU de Lille, Lille

69677

CHU de Lyon, Lyon

94000

APHP, Paris

06000

CHU de Nice, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT04159987 - Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA® | Biotech Hunter | Biotech Hunter